Dibutepinephrine (Anaphylm)
Small molecule
Evidence outlook · regulatory review
Anaphylaxis: application under FDA review, decision date 2027-03-16
FDA accepts the Anaphylm NDA resubmission (Class 2) (2026-10-15). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No matching registered study is currently available for this indication; source coverage requires resolution.
No registered study of this drug names Anaphylaxis in its conditions or title.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Alpha- and beta-adrenergic receptors (agonist) drugs
Epinephrine. Compare all 2 Alpha- and beta-adrenergic receptors (agonist) drugs
1 other tracked programme targets this mechanism.
This drug's own stage for Anaphylaxis: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dibutepinephrine (Anaphylm): this drug | Stage not on record | Small molecule | Alpha- and beta-adrenergic receptors (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Epinephrine (neffy) | Approved | Small molecule | Alpha- and beta-adrenergic receptors (agonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent